Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
Recruiting · NCT07784959 · Registry updated 2026-08-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of NXP900 With Lorlatinib in ALK+ Lung Cancer | non-small cell lung carcinoma | Recruiting | Phase 1 | 2026-08-25 | NCT07784959 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nuvectis Pharma, Inc. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| NEXT Virginia | Fairfax | United States | 83 |